Candriam S.C.A. Purchases 10,497 Shares of Oruka Therapeutics, Inc. $ORKA

Candriam S.C.A. increased its position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 2.6% in the 1st quarter, HoldingsChannel reports. The fund owned 411,006 shares of the company’s stock after acquiring an additional 10,497 shares during the period. Candriam S.C.A.’s holdings in Oruka Therapeutics were worth $20,160,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Viking Global Investors LP purchased a new stake in shares of Oruka Therapeutics during the 3rd quarter valued at $51,280,000. Paradigm Biocapital Advisors LP acquired a new position in Oruka Therapeutics during the 4th quarter valued at about $51,840,000. Remedium Capital Partners LLC purchased a new stake in Oruka Therapeutics in the fourth quarter valued at about $47,054,000. Avoro Capital Advisors LLC acquired a new stake in Oruka Therapeutics in the third quarter worth about $25,640,000. Finally, Deep Track Capital LP grew its stake in shares of Oruka Therapeutics by 38.4% during the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after acquiring an additional 735,983 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ORKA. HC Wainwright reiterated a “buy” rating and issued a $120.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, June 23rd. UBS Group lifted their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Piper Sandler reiterated an “overweight” rating and set a $180.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Leerink Partners set a $120.00 price objective on Oruka Therapeutics in a research note on Thursday, April 30th. Finally, Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Oruka Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $134.30.

Oruka Therapeutics Trading Down 1.7%

ORKA traded down $1.48 during midday trading on Friday, hitting $86.79. 503,020 shares of the company were exchanged, compared to its average volume of 1,747,588. The company’s 50 day simple moving average is $70.54 and its 200 day simple moving average is $51.36. The firm has a market capitalization of $5.23 billion, a price-to-earnings ratio of -44.74 and a beta of -0.35. Oruka Therapeutics, Inc. has a 1-year low of $12.84 and a 1-year high of $97.78.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. On average, equities analysts anticipate that Oruka Therapeutics, Inc. will post -2.06 EPS for the current year.

Insider Activity

In related news, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $69.69, for a total transaction of $120,494.01. Following the sale, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at approximately $64,503,670.20. This represents a 0.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Arjun Agarwal sold 10,290 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $59.07, for a total transaction of $607,830.30. Following the sale, the senior vice president owned 16,406 shares in the company, valued at approximately $969,102.42. This represents a 38.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 185,407 shares of company stock valued at $11,636,307. 23.49% of the stock is currently owned by company insiders.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.